桥粒芯蛋白2在胆管癌中的表达及其临床意义

Expression of desmoglein-2 in cholangiocarcinoma and its clinical significance

目的探讨桥粒芯糖蛋白2(DSG2)在胆管癌组织中的表达及临床意义。方法选取141例胆管癌患者作为研究对象,采用免疫组织化学法检测DSG2在胆管癌组织中的表达情况。结果胆管癌组织中DSG2的高表达率高于癌旁正常组织(P<0.05)。不同性别、年龄、组织学分级、T分期胆管癌患者胆管癌组织中DSG2的高表达率比较,差异均无统计学意义(P>0.05);N0、M0、TNM分期为Ⅰ～Ⅱ期胆管癌患者胆管癌组织中DSG2的高表达率均高于N1、M1、TNM分期为Ⅲ～Ⅳ期胆管癌患者,差异均有统计学意义(P<0.05)。单因素分析结果显示:不同性别、组织学分级、年龄、M分期胆管癌患者的总生存期比较,差异均无统计学意义(P>0.05);不同DSG2表达情况、T分期、N分期、TNM分期胆管癌患者的总生存期比较,差异均有统计学意义(P<0.05)。多因素分析结果显示:DSG2低表达为影响胆管癌患者生存的独立危险因素(P<0.05)。结论 DSG2在胆管癌中异常表达,可能与胆管癌的发生、发展相关,推测其可能作为胆管癌的一种新型肿瘤标志物,为胆管癌的诊治以及预后评估提供一个新的思路。

Objective To investigate the expression of desmoglein-2 （DSG-2） in cholangiocarcinoma and the correlation of expression of DSG-2 with cholangiocarcinoma. Method The clinical data of 141 patients with cholangiocarcinoma were enrolled. Immunohistochemical method was used to detect the expression level of the collected tissue specimens. Result The high expression rate of DSG-2 in the tissue of cholangiocarcinoma of patients was significantly higher than that in the adjacent mucosa （P〈0.05）. There was no significant difference in high expression rate of DSG-2 among patients with different sex, age, histological grading, T staging （P〉0.05）. The high expression rates of DSG-2 in the tissue of cholangiocarcinoma of patients with stage N0, M0, and I-II were significantly higher than those in cholangiocarcinomap- atients with stage N1, M1, and III-IV （P〈0.05）. Univariate analysis indicated that there was no significant difference in overall survival among cholangiocarcinoma patients with different sex, histological grading, age, stage M （P〉0.05）. There was significant difference in overall survival among cholangiocarcinoma patients with different expression of DSG- 2, stage T, stage N, stage TNM （/）〈0.05）. Multivariate analysis shouted that the low expression level of DSG2 was an in- dependent risk factor for survival of patients with cholangiocarcinoma （P〈0.05）. Conclusion The abnormal expression of DSG2 in cholangiocarcinoma tissue may be closely related to the occurrence and development of cholangiocarcinoma. It may be a new biomarker for cholangiocarcinoma and provide a new cluefor the diagnosis, treatment and prognosis eval- uation of cholangiocarcinoma.